Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03795701 · ClinicalTrials.gov registry record · NA
To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity
A NA study, sponsored by Texas Tech University.
- Completed
- Registry status
- NA
- Development phase
- 73
- Enrollment target
NCT03795701 is a NA study that has completed, run by Texas Tech University. The registered enrollment target is 73 participants.
The verdict
NCT03795701, a NA study, has completed, sponsored by Texas Tech University.
- COMPLETED
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
Study Summary
The study is a single center, randomized, double blind, placebo controlled; parallel-group repeated measures design. Subjects will be randomly assigned to either Saxenda® or placebo group after baseline assessments. The study will consist of a 4-week partial dose period (Liraglutide 0.6mg, 1.2mg, 1.8mg, 2.4 mg) and a 12-week full-dose (Liraglutide 3.0 mg) period. The placebo group will administer equivalent volumes of the pre-filled solutions from pen-injector at the same time, using the same method during this period. The study proposes to identify factors contributing to early weight loss response in a Saxenda® treatment program. Specifically, the proposed experiments will help determine if Saxenda® changes brain functional Magnetic Resonance Imaging Food Cue Reactivity (fMRI-FCR) and whether the magnitude of that change is associated with changes in behavioral and physiological variables (hunger, satiety, cravings and weight loss).
Interventions
- OTHER Placebo
- DRUG Saxenda®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-01-08 |
| Est. Completion | 2022-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03795701
The ClinicalTrials.gov registry entry for NCT03795701 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03795701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03795701 about?
NCT03795701 is a clinical study titled "To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity". The study is a single center, randomized, double blind, placebo controlled; parallel-group repeated measures design. Subjects will be randomly assigned to either Saxenda® or placebo group after baseline assessments. The study will consist of a 4-week partial dose period (Liraglutide 0.6mg, 1.2mg, 1....
What is the current status of trial NCT03795701?
This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2019-01-08. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT03795701?
The interventions under investigation include: Placebo (OTHER), Saxenda® (DRUG).
Who is sponsoring clinical trial NCT03795701?
This trial is sponsored by Texas Tech University, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.